Aegerion Pharmaceuticals
Developing advanced therapeutics for cardiovascular and metabolic diseases.
Developing advanced therapeutics for cardiovascular and metabolic diseases.
Aegerion Pharmaceuticals is a biopharmaceutical company with a focus on developing advanced therapeutics for cardiovascular and metabolic diseases. Founded in 2005, the company is headquartered in Bridgewater, New Jersey. Aegerion has developed lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug designed to reduce serum lipids, including cholesterol and triglycerides. This drug aims to address conditions such as atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company is also dedicated to producing products for the assessment and treatment of hyperlipidemia. Aegerion Pharmaceuticals secured a $1.50M Venture Round investment on 11 October 2010. With its innovative approach to addressing cardiovascular and metabolic diseases, Aegerion Pharmaceuticals is a significant player in the Biotechnology, Health Care, and Health and Wellness industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $1.50M | - | 11 Oct 2010 | |
| Venture Round | $18.31M | - | 28 Jun 2010 | |
| Convertible Note | $3.76M | 4 |
|
18 Sep 2008 |
| Series B | $17.61M | 4 |
|
30 Nov 2007 |
| Series A | $22.50M | 2 |
|
13 Jun 2006 |
No recent news or press coverage available for Aegerion Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
